No title
The platelet-activating factor inhibitor BN50730, a hetrazepine, was injected intraperitoneally daily from 30 days of age into diabetes-prone BB rats. While 96% (22123) Tween 80 injected control rats developed diabetes, 0.05 mg/kg BN50730 decreased the frequency to 72% (17/24;n.s.) and 0.5 mg/kg to 56% (14125;p <0.01). Mean onset age in controls was 81 ± 9 days (mean ± SD), but BN50730 delayed ons
